Indevus trospium for OAB
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryIndevus submits an NDA for its oral antimuscarinic agent trospium for the treatment of overactive bladder April 28. A Phase III pivotal trial, presented at the American Urological Association April 28, showed statistically significant results for the dual pre-specified endpoints of reduction in frequency of urination (toilet voids) and reduction in number of urge incontinence episodes. At week 12, trospium patients had 2.37 fewer toilet voids per day than at baseline, versus 1.29 for placebo. Incontinence episodes were reduced 59% in trospium patients versus 44% in placebo patients. Indevus is claiming a favorable side effect profile; 21.8% of trospium patients experienced dry mouth and 9.5% experienced constipation in the pivotal trial. Trospium is currently marketed in Europ
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.